Abstract
ASHP supports the identification and treatment of H. pylori infection in appropriate patients as an effective method of reducing the morbidity and mortality associated with peptic ulcer disease. Successful and safe therapy requires extensive patient education and monitoring by qualified health care professionals to maximize patient understanding of and compliance with medication regimens and to minimize adverse events. Pharmacists are key to ensuring that patients use prescribed regimens appropriately so that H. pylori is eradicated and that clinical outcomes of associated peptic ulcer disease are optimal.
Author supplied keywords
- American Society of Health-System Pharmacists
- Amoxicillin
- Antacids
- Anti-infective agents
- Bismuth subsalicylate
- Clarithromycin
- Clinical pharmacists
- Combined therapy
- Gastrointestinal drugs
- Helicobacter infections
- Lansoprazole
- Macrolides
- Metronidazole
- Omeprazole
- Penicillins
- Proto cols
- Ranitidine bismuth citrate
- Tetracycline
- Tetracyclines
- Ulcers
Cite
CITATION STYLE
Buring, S., Russell, W., Meyer, J. M., & Segal, R. (2001). ASHP therapeutic position statement on the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults. American Journal of Health-System Pharmacy, 58(4), 331–337. https://doi.org/10.1093/ajhp/58.4.331
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.